Lipocomb

Ezetimibe and Rosuvastatin zinc, the active ingredient in Lipocomb, is a combination cholesterol absorption inhibitor and HMG‑CoA reductase inhibitor presented as a combination tablet for oral use. It treats hypercholesterolemia, mixed dyslipidemia and primary hyperlipidemia in adult patients.

GNH USA supplies Lipocomb as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Lipocomb, a combination lipid‑lowering agent, is used to manage disorders of cholesterol metabolism.

- Hypercholesterolemia: reduces LDL‑cholesterol and total cholesterol levels. - Mixed dyslipidemia: improves the lipid profile by lowering LDL‑C and triglycerides while raising HDL‑C. - Primary hyperlipidemia: helps achieve target lipid goals in patients with elevated cholesterol not controlled by diet alone.

Lipocomb may cause a range of adverse reactions, most of which are mild and reversible.

Common Side Effects: - Headache: mild to moderate intensity. - Myalgia: muscle aches without weakness. - Gastrointestinal discomfort: nausea, abdominal pain or diarrhoea. - Elevated liver enzymes: mild increases in ALT or AST. - Upper respiratory symptoms: nasopharyngitis or cough.

Serious or Rare Side Effects: - Rhabdomyolysis: severe muscle breakdown with dark urine. - Hepatotoxicity: marked elevation of liver transaminases or jaundice. - Severe allergic reactions: anaphylaxis, angioedema or skin rash.

Before prescribing Lipocomb, clinicians should evaluate patient history and laboratory values.

- Liver function: assess baseline ALT/AST and avoid use in active liver disease. - Muscle disorders: monitor for signs of myopathy, especially if combined with other lipid‑lowering agents. - Renal impairment: adjust monitoring in patients with severe renal dysfunction. - Pregnancy and lactation: avoid use due to insufficient safety data. - Drug interactions: review concomitant medications that affect statin metabolism. - Store at ambient temperature: keep below 25 °C, retain in original packaging, protect from moisture and direct sunlight.

Lipocomb can interact with several drug classes, requiring careful management.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., clarithromycin, itraconazole): may increase rosuvastatin exposure and risk of myopathy. - Cyclosporine: markedly raises rosuvastatin plasma levels, increasing toxicity. - Gemfibrozil: combined use heightens risk of muscle injury.

Moderate Interactions (Monitor Closely): - Antacids containing aluminum or magnesium: may reduce ezetimibe absorption. - Warfarin: monitor INR as lipid‑lowering therapy can affect anticoagulation. - Niacin: may increase risk of liver enzyme elevations.